However, this increase in demand has had a notable impact on overall pharmacy spending, making it essential for employers to pay attention to how these drugs affect their health care costs
Gastrointestinal adverse events drive 9% to 14% of initiated patients to permanently discontinue GLP-1 therapy
The most commonly reported changes after stopping GLP-1 medications include: Return of appetite : The appetite-suppressing effects diminish, and many people notice increased hunger and food cravings returning to pre-treatment levels Weight regain : Clinical evidence consistently shows that most individuals regain weight after discontinuation, often within 312 months Rising blood glucose levels : For those with type 2 diabetes, HbA1c levels typically increase, sometimes returning to pre-treatment values Changes in eating patterns : Gastric emptying returns to normal speed, which may affect feelings of fullness after meals It's important to note that stopping GLP-1 medications is generally safe from a withdrawal perspectivethese drugs do not cause physical dependence or withdrawal symptoms in the way some medications do, and tapering is not typically required
Call or email us and we will verify your insurance prior to your appointment
If a patient takes a drug that is available in a non-oral formulation (e.g., transdermal estradiol instead of oral estradiol, patch-based hormone therapy instead of oral HRT), switching reduces the interaction risk without requiring drug-level monitoring
